Insulin Glargine (Genetical Recombination) Injection 450 Units/1.5mL (Lantus XR SoloStar® / ランタスXR注ソロスター)

JPY ¥5,000

Japanese long-acting soluble insulin analog preparation (Insulin Glargine (Genetical Recombination) 450 Units/1.5mL). Subcutaneous injection for diabetes mellitus requiring insulin therapy. 1.5mL x 2 pens. Mfd. by Sanofi K.K., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥4,600
10 - 19 12% JPY ¥4,400
20 + 18% JPY ¥4,100
SKU: LXR-450-INJ Category:

Description

Product Overview / 商品概要

Lantus XR SoloStar S.C. Injection 450 Units/1.5mL (ランタスXR注ソロスター)
Generic: Insulin Glargine (Genetical Recombination) / インスリン グラルギン(遺伝子組換え)
Therapeutic Category: Long-acting soluble insulin analog preparation / 持効型溶解インスリンアナログ製剤
Manufactured by: Sanofi K.K. / サノフィ株式会社

Composition & Specification / 組成・規格

Active Ingredient: Insulin Glargine (Genetical Recombination) 450 Units per 1 kit (1.5mL) / 1キット(1.5mL)中 日局インスリン グラルギン(遺伝子組換え)450単位
Additives: m-Cresol 4.05mg, Zinc chloride (as zinc content) 0.135mg, Glycerin 30mg, pH adjusters (2 components) q.s. / m-クレゾール 4.05mg、塩化亜鉛(亜鉛含量として)0.135mg、グリセリン 30mg、pH調節剤 2成分 適量
Appearance: Colorless clear solution (injection); pH 3.5–4.5; osmotic pressure ratio approx. 0.8 (relative to physiological saline)
外観: 無色澄明の液(注射剤)、pH 3.5〜4.5、浸透圧比 約0.8(生理食塩液に対する比)

Indications / 効能効果

EN: Diabetes mellitus requiring insulin therapy
JA: インスリン療法が適応となる糖尿病

Dosage and Administration / 用法用量

EN: In adults, the usual initial dose is 4 to 20 units subcutaneously once daily; other insulin preparations may be used concomitantly. The injection time should be consistent each day. The dose should be adjusted according to the patient’s condition and laboratory findings. The usual maintenance dose, including doses of other insulin preparations, is 4 to 80 units per day. If necessary, doses exceeding the above may be used.
JA: 通常、成人では、初期は1日1回4〜20単位を皮下注射するが、ときに他のインスリン製剤を併用することがある。注射時刻は毎日一定とする。投与量は、患者の症状及び検査所見に応じて増減する。なお、その他のインスリン製剤の投与量を含めた維持量は、通常1日4〜80単位である。ただし、必要により上記用量を超えて使用することがある。

Contraindications / 禁忌

EN: 2.1 Patients with hypoglycemic symptoms; 2.2 Patients with a history of hypersensitivity to any component of this product or other insulin glargine preparations
JA: 2.1 低血糖症状を呈している患者、2.2 本剤の成分又は他のインスリン グラルギン製剤に対し過敏症の既往歴のある患者

Regulatory Information / 規制情報

Approval No.: 22700AMX00700
Sales Started: September 2015 / 2015年9月
Classification Code: 872492
Storage: Store at 2–8°C; do not freeze / 凍結を避け、2〜8℃で保存
Shelf Life: 24 months / 24箇月

Packaging / 包装

Main Package (for sale): 1.5mL x 2 pens / 1.5mL×2本
Other Available Packages (by special order): 1.5mL x 2 pens

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Insulin Glargine (Genetical Recombination) Injection 450 Units/1.5mL (Lantus XR SoloStar® / ランタスXR注ソロスター)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Insulin Glargine (Genetical Recombination) Injection 450 Units

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.